|
According to IMS HEALTH's LifeCycle
service, the US was the first market for two of the 1999 biotech
new active substances, as was Germany. Canada, Japan and the
UK all saw the first launch of one new biotech NAS.
In contrast, in 1998 most of the 14 biotechnology drugs were
introduced in the US first and by the end of 1998 had not
penetrated other world markets:
- Simulect (basiliximab) from Novartis/Seragen is indicated
for prophylaxis of acute organ rejection in renal transplantation.
It was first introduced in Switzerland in April 1998 and
was on the market in several European countries, the US,
and Brazil by year end.
- Zenapax (daclizumab) was introduced in the US in January
1998, also for prevention of kidney transplant rejection.
It was subsequently launched in Switzerland, Germany and
Thailand by the end of 1998.
- Chiron's Regranex (becaplermin) was first introduced
in the US and later in 1998 in Canada and Puerto Rico
Although sales of these biotech products are quite modest
at present, a number of biotechnology NASs have made their
mark financially.
At least seven such products were in the Top 50 table of new
drugs introduced over the last five years in terms of world
dollar sales, according to IMS HEALTH's 1998 Pharmaceutical
World Review.
Leading Biotechnology Products (Launched
in the Last Five Years) in 1998
| Product |
Original
Marketing Company |
Active
Ingredient |
Therapy
Class |
Rank
within 50 Leading 1998 NAS |
| ReoPro |
Lilly |
abciximab |
B1
|
13
|
| Avonex |
Biogen |
interferon
beta-1a |
L3
|
17
|
| GONAL-F |
Ares-Serono |
follitropin
alfa |
G3
|
28
|
| Singulair |
Merck
& Co |
montelukast |
R3
|
33
|
| Accolate |
Zeneca |
zafirlukast |
R3
|
41
|
| Humalog |
Lilly |
insulin
lispro |
A10
|
45
|
| Pulmozyme |
Genentech/Roche |
dornase
alfa |
R5
|
50
|
Source:
IMS HEALTH Pharmaceutical World Review 1998
ReoPro, first introduced in 1995, was ranked 13th
best selling new active substance in 1998 with sales topping
US$300 million. Biogen's Avonex commanded sales of
US$268 million in 1998.
Other biotech NASs ranked in the top 50 all had sales well
over US$100 million in 1998. The NEW 1999 Pharmaceutical
World Review will be available in April 2000.
07 Mar 2000, Copyright IMS HEALTH
|
